New cocktail of drugs shows promise for tough pancreatic cancer

NCT ID NCT05014776

First seen Mar 05, 2026 · Last updated May 15, 2026 · Updated 5 times

Summary

This study tested a combination of four drugs (CRS-207, pembrolizumab, ipilimumab, and tadalafil) in 17 adults with metastatic pancreatic cancer that had worsened after at least one prior chemotherapy. The goal was to see if the treatment could shrink tumors and to check its safety. The approach aims to boost the immune system to fight the cancer, but ongoing management is still needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland, 21231, United States

Conditions

Explore the condition pages connected to this study.